Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06561009 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 1, 2026 to Oct 1, 2027
    • Start date: Oct 1, 2024 to Dec 1, 2025
    • Study completion date: Oct 1, 2027 to Oct 1, 2028
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, single-arm, dose-escalation study in up to 20 participants with relapsed/refractory Neuromyelitis Optica Spectrum Disorders (NMOSD). The aim is to evaluate the safety and efficacy of the treatment with BAFFR CART.
Trial Details
NCT Number NCT06561009
Lead Sponsor Tianjin Medical University General Hospital
Conditions
(from sponsor)		 Neuromyelitis Optica Spectrum Disorder
Related terms Neuromyelitis Optica
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov